Swati Biswas, and Vladimir P. Torchilin. "Current trends in the use of liposomes for tumor
targeting." Nanomedicine 8.9 (2013): 1509-1528.
Ferrari, M. (2005). Cancer nanotechnology: opportunities and challenges. Nature Reviews Cancer,
5(3), 161-171.
Gonzalez-Angulo, A. M., Litton, J. K., Broglio, K. R., Meric-Bernstam, F., Rakkhit, R., Cardoso,
F., ... & Hortobagyi, G. N. (2009). High risk of recurrence for patients with breast cancer who
have human epidermal growth factor receptor 2–positive, node-negative tumors 1 cm or
smaller. Journal of clinical oncology, 27(34), 5700-5706.
Guyton, A., & Hall, J. (2006). Textbook of medical physiology (11th ed.). Philadelphia, Pennsylvania:
Elsevier Saunders.
HER2 Status and Breast Cancer. (n.d.). Retrieved October 15, 2015,
from http://www.breastcancer.org/symptoms/diagnosis/her2
Keefe, D. L. (2002). Trastuzumab-associated cardiotoxicity. Cancer, 95(7), 1592-1600.
Kiyomiya, K. I., Matsuo, S., & Kurebe, M. (2001). Mechanism of specific nuclear transport of
adriamycin the mode of nuclear translocation of adriamycin-proteasome complex. Cancer
research, 61(6), 2467-2471.
Martín, M., Sánchez-Rovira, P., Muñoz, M., Mel, J. R., Margeli, M., Ramos, M., ... & Carrasco, E.
(2011). Pegylated liposomal doxorubicin in combination with cyclophosphamide and
trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety
from the GEICAM/2004–05 study. Annals of oncology, 22(12), 2591-2596.
Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. (2001).
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal
and activated Her2 ectodomain cleavage in breast cancer cells. Cancer research, 61(12), 47444749.
Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. (2014 March).
Retrieved October 19, 2015, from
http://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-riskreduction/tools/cohort